Australia markets closed

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3100+0.0100 (+0.43%)
At close: 04:00PM EST
2.3100 0.00 (0.00%)
After hours: 04:02PM EST

PMV Pharmaceuticals, Inc.

8 Clarke Drive
Suite 3
Cranbury, NJ 08512
United States
609 642 6670

Full-time employees62

Key executives

NameTitlePayExercisedYear born
Dr. David H. Mack Ph.D.Co-Founder, CEO, President & Director762.02kN/A1962
Dr. Arnold J. Levine Ph.D.Co-Founder, Director & Member of Scientific Advisory Board140kN/A1940
Mr. Winston Kung M.B.A.COO & CFO591.29kN/A1976
Dr. Leila Alland M.D.Chief Medical Officer601.93kN/A1963
Dr. Thomas E. Shenk Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1947
Mr. Robert TicktinGeneral Counsel & Company SecretaryN/AN/A1962
Mr. Tim SmithSenior VP & Head of Corporate DevelopmentN/AN/AN/A
Ms. Crystal ZuckermanVice President of Human ResourcesN/AN/AN/A
Dr. Binh Vu Ph.D.Senior VP of Drug Discovery & CMCN/AN/AN/A
Dr. Deepika Jalota Pharm.D.Chief Development Officer579.96k87.59k1977
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

Corporate governance

PMV Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.